Hepatitis C: all 2,356 studies

Page 20 of 24. Open to participants first (101), then studies with results posted, then the rest; newest registration first within each.

• Clinical Performance of Abbott RealTime Hepatitis C Virus (HCV) Genotype II TestCompletedNCT00979979
• SPC3649 Multiple Dose Study in Healthy VolunteersCompletedNCT00979927Phase 1
• Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV InfectionCompletedNCT00978497Phase 2
• Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral LoadTerminatedNCT00977054Phase 4
• Identifying the Gaps in the Diagnosis and Management of Hepatitis CWithdrawnNCT00976781
• VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy VolunteersCompletedNCT00973388Phase 1
• Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C VirusCompletedNCT00971308Phase 1
• Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have RelapsedCompletedNCT00968357Phase 2
• A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus InfectionCompletedNCT00963885Phase 2
• Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I InfectionTerminatedNCT00962936Phase 1/2
• Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting ConditionsCompletedNCT00960479Phase 1
• Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting ConditionsCompletedNCT00959933Phase 1
• Alcohol Use Reduction in Methadone Individuals With Hepatitis C Virus(HCV)CompletedNCT00958763Phase 2
• Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy SubjectsCompletedNCT00958152Phase 1
• Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian EthnicityCompletedNCT00957866Phase 4
• PEG-IFN Plus Ribavirin Combination Therapy for Older PatientsStatus unknownNCT00956982Not applicable
• Hyperimmune Bovine Colostrum - TRAVELAN™ for Patients With Chronic Hepatitis C Virus Infection Not Responding to Standard TherapyWithdrawnNCT00956722Phase 1
• 480 STUDY: Phase 2b Study of Locteron Plus Ribavirin to Treat Hepatitis C Virus (HCV)CompletedNCT00953589Phase 2
• Study in Healthy Volunteers to Evaluate a Human Monoclonal Antibody Against Hepatitis CCompletedNCT00952263Phase 1
• Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep CWithdrawnNCT00951223
• Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis CCompletedNCT00948220Phase 4
• Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule FormulationCompletedNCT00947440Phase 1
• Japanese Bridging Study Conducted in the United StatesWithdrawnNCT00947245Phase 1
• Investigation of Hepatitis B and Hepatitis C in TaiwanCompletedNCT00946010
• Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-NaiveCompletedNCT00945880Phase 1
• High Dose Ribavirin in the Treatment of Chronic Hepatitis CCompletedNCT00944684Phase 2
• A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis CCompletedNCT00940420Phase 4
• TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated DosingCompletedNCT00938899Phase 1
• VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and EscitalopramCompletedNCT00933894Phase 1
• Study in Healthy Adults to Evaluate Pharmacokinetics, Safety and Tolerability of ABT-450 With RitonavirCompletedNCT00931281Phase 1
• Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis CWithdrawnNCT00930995Phase 2
• Pioglitazone vs. Placebo in Association With Pegylated Interferon and Ribavirin in HCV Patients With Insulin ResistanceTerminatedNCT00927290Phase 3
• Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/RibaCompletedNCT00926614Phase 4
• Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIVCompletedNCT00926146Not applicable
• The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHCCompletedNCT00926120Phase 2
• Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 SubjectsCompletedNCT00926016Not applicable
• A Study of Single Dose of ABT-333 in Healthy Male AdultsCompletedNCT00919490Phase 1
• Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)CompletedNCT00918476Phase 1
• Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis CCompletedNCT00917358Phase 4
• Virology Follow up Study in Subjects Previously Treated With TelaprevirCompletedNCT00916474
• A Study to Investigate the Potential Pharmacokinetic Interaction Between TMC435 and MethadoneCompletedNCT00915564Phase 1
• Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C InfectionCompletedNCT00911963Phase 1/2
• Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis CCompletedNCT00910975Phase 4
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 TabletCompletedNCT00909636Phase 1
• Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With RitonavirCompletedNCT00909311Phase 1
• Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV TreatmentCompletedNCT00909129Not applicable
• Drug-Drug Interaction Study in Healthy SubjectsCompletedNCT00904059Phase 1
• VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.CompletedNCT00903773Phase 1
• ANRS HC20 Effectiveness of an Optimized Anti HCV PegIFN-alpha2a + Ribavirin on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and Co-infected With HIVCompletedNCT00901524Phase 2
• Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)WithdrawnNCT00895882Phase 2
• Bioavailability of ABT-333 Tablet Versus First in Human (FIH) Capsule Formulation and Safety, Tolerability and PK Study of Single Doses of ABT-333 in Healthy VolunteersCompletedNCT00895102Phase 1
• Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European PopulationCompletedNCT00894257
• Metabolic Viral Host PropertiesCompletedNCT00893308
• A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis CCompletedNCT00890318Phase 1
• Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/RelapsersTerminatedNCT00882193Early Phase 1
• Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant PatientsCompletedNCT00881582Phase 4
• Interaction of Alcohol and Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS and HIV/AIDS With Hepatitis C Virus (HCV) Co-InfectionCompletedNCT00879047Phase 1
• Effects of Genotypes on Interferon Signaling in Chronic Hepatitis CWithdrawnNCT00876174
• Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus InfectionTerminatedNCT00874796Phase 2
• A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 StudiesCompletedNCT00872196Phase 2
• A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4CompletedNCT00869661Phase 2
• Prediction of Hepatitis C Recurrence in Liver Transplant RecipientsTerminatedNCT00867243
• TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.CompletedNCT00866853Phase 1
• Phase 2B Dose Ranging Study of Locteron Plus Ribavirin to Treat HCVCompletedNCT00863239Phase 2
• Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed StateCompletedNCT00861458Phase 1
• Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon ResistanceStatus unknownNCT00856804Phase 2
• A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 PatientsCompletedNCT00854802Not applicable
• Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1CompletedNCT00850044Phase 1
• Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral TreatmentCompletedNCT00844272Phase 4
• Impact of Hepatitis C Virus Variability on SteatosisTerminatedNCT00843076
• Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) InfectionStatus unknownNCT00842205Not applicable
• An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug UsersCompletedNCT00841477Phase 3
• Nutritional Support During Antiviral Therapy for Hepatitis CStatus unknownNCT00841243Phase 4
• Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced FibrosisTerminatedNCT00840489Phase 2
• Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular CarcinomaStatus unknownNCT00834860Phase 4
• Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.CompletedNCT00833378Phase 1
• High Dose Versus Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3CompletedNCT00830609Phase 4
• VX-950-TiDP24-C134: Drug-drug Interaction Trial Between Combination of Efavirenz and Tenofovir Disoproxil Fumarate and Different Dosages of Telaprevir on Healthy VolunteerCompletedNCT00828789Phase 1
• Evaluation of RNA From the Liver Tissue Obtained in Patients With Chronic Hepatitis C (0000-123)CompletedNCT00828269Phase 1
• Long-term Follow-up of HALT-C Sustained Virological RespondersCompletedNCT00825877
• Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) InfectionCompletedNCT00823862Phase 1
• Sonazoid Enhanced Liver Cancer Trial for Early DetectionStatus unknownNCT00822991Not applicable
• Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin InhibitorsCompletedNCT00819026
• A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis CWithdrawnNCT00814606Phase 2
• Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED)TerminatedNCT00811967Phase 3
• Study of Maternal Hepatitis C Infection and Influenza Vaccination in PregnancyTerminatedNCT00810875
• Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691CompletedNCT00810758Phase 1
• Vitamin D Treatment in Patients With Chronic Hepatitis CStatus unknownNCT00804752Not applicable
• Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 PatientsTerminatedNCT00803309Phase 4
• A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C PatientsCompletedNCT00801255Phase 1
• A Study of Combination Treatment With Peginterferon Alfa-2a (Pegasys) Plus Ribavirin (Copegus) in Participants With Chronic Hepatitis CCompletedNCT00800748Phase 4
• Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C VirusTerminatedNCT00800007Phase 1/2
• A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED)CompletedNCT00797745Phase 2
• Quality of Life Therapy for Adults With Hepatitis C Virus and Cirrhosis Awaiting Liver TransplantationCompletedNCT00794911Not applicable
• Effects of Motivational Interviewing on Risky Injecting Practices Among Injecting Drug Users (IDUs)CompletedNCT00794391Not applicable
• Study of Cerebral Function in Patients With Chronic Hepatitis C Infection (HCV/CNS)CompletedNCT00788918Not applicable
• Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)CompletedNCT00787371Phase 2
• Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV InfectionCompletedNCT00782353Phase 1
• Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected PatientsWithdrawnNCT00782301Phase 4
• Antiviral Activity of AZD7295 in HCV CarriersCompletedNCT00781976Phase 1

← Hepatitis C overview